Ubiquitin-conjugating enzyme promotes chromosome missegregation and tumor formation

A ubiquitin-conjugating enzyme that regulates the cell cycle promotes chromosome missegregation and tumor formation, according to van Ree et al. in the January 11 issue of the Journal of Cell Biology (www.jcb.org).

The mitotic E2 enzyme UbcH10 partners with the anaphase-promoting complex/cyclosome (APC/C) to ubiquitinate cell cycle regulators, targeting them for proteasomal destruction, and ensuring progression through mitosis. UbcH10 is overexpressed in a variety of human cancers, but whether it causes tumors or is simply up-regulated due to the increased number of proliferating cancer cells is unknown.

van Ree et al. generated mice expressing high levels of UbcH10 and found that they formed tumors in a broad range of tissues. Many of these tumors displayed aneuploidy-abnormal numbers of chromosomes resulting from errors in cell division. Live microscopy showed that cells expressing high amounts of UbcH10 had problems segregating sister chromatids correctly, possibly because the cells contained extra numbers of centrosomes that might complicate formation of a normal mitotic spindle. UbcH10 overexpression also reduced levels of the mitotic regulator cyclinB-a substrate of the APC/C-though it remains to be seen if this contributes directly to centrosome amplification and aneuploidy.

The same research group recently demonstrated that chromosome segregation defects drive tumorigenesis by promoting the loss of tumor suppressor genes like p53. Senior author Jan van Deursen now wants to investigate whether UbcH10 synergizes with other factors to promote chromosome instability in human cancers.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Successful treatment of metastatic malignant glomus tumor with BRAF and MEK inhibitors